Treats chronic idiopathic constipation (CIC). ANDA 219234, held by Alembic. Prucalopride Succinate.
As of Nov 16, 2026, ANDA 219234 (Prucalopride Succinate), held by Alembic, was first approved by FDA on Jul 27, 2026, with 0 approved supplements and 0 published complete response letters.
Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 27, 2026 | Original application | Approved | None posted |
| Prucalopride SuccinateEQ 1MG BASE · tablet;oral | Prucalopride Succinate | Rx |
| Prucalopride SuccinateEQ 2MG BASE · tablet;oral | Prucalopride Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters